NCT06519968View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
Healthy Participants
Interventions
DRUG

AZD4604

AZD4604 will be administered as Dry Powder Inhalation (DPI).

DRUG

Placebo

Placebo will be administered as DPI.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY